+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Analysis of clinical variables associated with tolerance in pediatric liver transplant recipients



Analysis of clinical variables associated with tolerance in pediatric liver transplant recipients



Pediatric Transplantation 14(8): 976-979



Tolerance has been defined as stable graft function off IMS. We reviewed the data of 369 pediatric liver transplant patients to examine demographic differences that may have a PV of pediatric LT tolerance. Of the 369 patients, 280 patients were stable with detectable blood levels of IMS agents and with good graft function without biopsy proven REJ > 1 yr posttransplantation, 18 patients were noted to be TOL off IMS, 27 patients were taking MIS with drug levels below detectable range by standard laboratory parameters, and 44 patients developed one or more episodes of biopsy proven acute or chronic REJ > 1 yr post-transplantation. Variables, including percentage of biliary atresia, type of transplanted organ, history of EBV infection, patient and donor gender, and ABO blood type mismatch between recipient and donor did not have PV of tolerance. Average age in years was 1.37 ± 1.53 (0.3-4.9) for TOL, 1.14 ± 0.89 (0.4-3.1) for MIS and 3.35 ± 4.45 (0.3-16) for REJ. Age difference of TOL/MIS vs. REJ was significant (p =0.002) and TOL vs. REJ was significant (0.01). Age at the time of transplantation is an important predictor in the development of pediatric LT tolerance.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051520626

Download citation: RISBibTeXText

PMID: 21108705

DOI: 10.1111/j.1399-3046.2010.01360.x


Related references

An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 68(5): 650-655, 1999

Longitudinal evaluation of mycophenolic acid pharmacokinetics in pediatric kidney transplant recipients. The role of post-transplant clinical and therapeutic variables. Clinical Transplantation 23(2): 264-270, 2009

Approaching operational tolerance in long-term pediatric liver transplant recipients receiving minimal immunosuppression. Transplantation Proceedings 29(1-2): 449-451, 1997

Impact of pre-transplant liver hemodynamics and portal reconstruction techniques on post-transplant portal vein complications in pediatric liver transplantation: a retrospective analysis in 197 recipients. Annals of Surgery 254(1): 55-61, 2011

Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort. Transplant Infectious Disease 20(1):, 2018

Pediatric liver transplant recipients: mortality analysis over 20 years. Journal of Insurance Medicine 38(1): 3-8, 2006

Longterm outcomes for whole and segmental liver grafts in adult and pediatric liver transplant recipients: a 10-year comparative analysis of 2,988 cases. Journal of the American College of Surgeons 208(5): 682-9; Discusion 689-91, 2009

Clinical features of nosocomial rotavirus infection in pediatric liver transplant recipients. Clinical Transplantation 9(3 Pt 1): 201-204, 1995

Epidemiology and clinical features of post-transplant bloodstream infection: an analysis of 222 consecutive liver transplant recipients. Infection and ChemoTherapy 45(3): 315-324, 2013

Pre-transplant variables predict qualify of life in liver transplant recipients. 2007

Analysis of the CC chemokine receptor 5Delta32 polymorphism in pediatric liver transplant recipients. Pediatric Transplantation 12(7): 769-772, 2008

Clinical consequences of human herpesvirus-6 DNAemia in peripheral blood in pediatric liver transplant recipients. Pediatric Transplantation 18(1): 47-51, 2014

Cost benefit analysis of varicella vaccine in pediatric liver and kidney transplant recipients. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 31: 285, 1991

Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience. Transplantation Proceedings 42(5): 1763-1768, 2010

Studies of Pediatric Liver Transplantation 2002: patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada. Pediatric Transplantation 8(3): 273-283, 2004